Nomura Incrementally More Bullish on BioMarin's (BMRN) Drisapersen Approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Plug Power COO resigns to join another company
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
Baird Downgrades BioMarin Pharmaceutical Inc. (BMRN) to Neutral
June 19, 2015 6:27 AM EDTBaird transferred coverage and downgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Outperform to Neutral with a price target of $133.00 (from $125.00). The firm cited valuation.
Analyst Brian Skorney commented, "With shares currently trading around $138 and our... More
